Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Clinical trial NCT04040725 · WITHDRAWN
Trial details
- NCT number
- NCT04040725
- Sponsor
- Dana-Farber Cancer Institute
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-27
- Primary completion
- 2019-11-27
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.